{"downloaded": true, "htmlmade": false, "full": {"id": "29326124", "source": "MED", "pmid": "29326124", "pmcid": "PMC5830392", "fullTextIdList": {"fullTextId": "PMC5830392"}, "doi": "10.3324/haematol.2017.176859", "title": "Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.", "authorString": "Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Rai SC, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, Alyea EP.", "authorList": {"author": [{"fullName": "Koreth J", "firstName": "John", "lastName": "Koreth", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA john_koreth@dfci.harvard.edu."}}}, {"fullName": "Kim HT", "firstName": "Haesook T", "lastName": "Kim", "initials": "HT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA."}}}, {"fullName": "Lange PB", "firstName": "Paulina B", "lastName": "Lange", "initials": "PB", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Poryanda SJ", "firstName": "Samuel J", "lastName": "Poryanda", "initials": "SJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Reynolds CG", "firstName": "Carol G", "lastName": "Reynolds", "initials": "CG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Rai SC", "firstName": "Sharmila Chamling", "lastName": "Rai", "initials": "SC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Armand P", "firstName": "Philippe", "lastName": "Armand", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Cutler CS", "firstName": "Corey S", "lastName": "Cutler", "initials": "CS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Ho VT", "firstName": "Vincent T", "lastName": "Ho", "initials": "VT", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Glotzbecker B", "firstName": "Brett", "lastName": "Glotzbecker", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Yusuf R", "firstName": "Rushdia", "lastName": "Yusuf", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Nikiforow S", "firstName": "Sarah", "lastName": "Nikiforow", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Chen YB", "firstName": "Yi-Bin", "lastName": "Chen", "initials": "YB", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA."}}}, {"fullName": "Dey B", "firstName": "Bimalangshu", "lastName": "Dey", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Massachusetts General Hospital Cancer Center, Boston, MA."}}}, {"fullName": "McMasters M", "firstName": "Malgorzata", "lastName": "McMasters", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Beth Israel Deaconess Hospital Cancer Center, Boston, MA."}}}, {"fullName": "Ritz J", "firstName": "Jerome", "lastName": "Ritz", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Blazar BR", "firstName": "Bruce R", "lastName": "Blazar", "initials": "BR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Minnesota Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, Minneapolis, MN, USA."}}}, {"fullName": "Soiffer RJ", "firstName": "Robert J", "lastName": "Soiffer", "initials": "RJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Antin JH", "firstName": "Joseph H", "lastName": "Antin", "initials": "JH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}, {"fullName": "Alyea EP 3rd", "firstName": "Edwin P", "lastName": "Alyea", "initials": "EP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "3", "volume": "103", "journalIssueId": "2655459", "dateOfPublication": "2018 Mar", "monthOfPublication": "3", "yearOfPublication": "2018", "printPublicationDate": "2018-03-01", "journal": {"title": "Haematologica", "ISOAbbreviation": "Haematologica", "medlineAbbreviation": "Haematologica", "NLMid": "0417435", "ISSN": "0390-6078", "ESSN": "1592-8721"}}, "pubYear": "2018", "pageInfo": "522-530", "abstractText": "Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft-<i>versus</i>-host disease incidence, with promising overall and progression-free survival. We performed an open-label three-arm 1:1:1 phase II randomized controlled trial comparing grade II-IV acute graft-<i>versus</i>-host disease between conventional tacrolimus/methotrexate (A) <i>versus</i> bortezomib/tacrolimus/methotrexate (B), and <i>versus</i> bortezomib/sirolimus/tacrolimus (C), in reduced intensity conditioning allogeneic transplantation recipients lacking HLA-matched related donors. The primary endpoint was grade II-IV acute graft-<i>versus</i>-host disease incidence rate by day +180. One hundred and thirty-eight patients (A 46, B 45, C 47) with a median age of 64 years (range: 24-75), varying malignant diagnoses and disease risk (low 14, intermediate 96, high/very high 28) received 7-8/8 HLA-mismatched (40) or matched unrelated donor (98) grafts. Median follow up in survivors was 30 months (range: 14-46). Despite early immune reconstitution differences, day +180 grade II-IV acute graft-<i>versus</i>-host disease rates were similar (A 32.6%, B 31.1%, C 21%; <i>P</i>=0.53 for A <i>vs</i> B, <i>P</i>=0.16 for A <i>vs</i> C). The 2-year non-relapse mortality incidence was similar (A 14%, B 16%, C 6.4%; <i>P</i>=0.62), as were relapse (A 32%, B 32%, C 38%; <i>P</i>=0.74), chronic graft-<i>versus</i>-host disease (A 59%, B 60% C 55%; <i>P</i>=0.66), progression-free survival (A 54%, B 52%, C 55%; <i>P</i>=0.95), and overall survival (A 61%, B 62%, C 62%; <i>P</i>=0.98). Overall, the bortezomib-based regimens evaluated did not improve outcomes compared with tacrolimus/methotrexate therapy. <i>clinicaltrials.gov Identifier: 01754389</i>.", "affiliation": "Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA john_koreth@dfci.harvard.edu.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "R01 CA183559", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P01 CA142106", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "R01 CA183560", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "R01 HL118979", "agency": "NHLBI NIH HHS", "acronym": "HL", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Hematologic Diseases", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Graft vs Host Disease", "meshQualifierList": {"meshQualifier": {"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Tacrolimus", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Methotrexate", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Immunosuppression", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Transplantation Conditioning", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Transplantation", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Survival Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Allografts"}, {"majorTopic_YN": "N", "descriptorName": "Bortezomib", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}]}, "chemicalList": {"chemical": [{"name": "Methotrexate", "registryNumber": "YL5FZ2Y5U1"}, {"name": "Tacrolimus", "registryNumber": "WM0HAQ4WNM"}, {"name": "bortezomib", "registryNumber": "69G8BD63PP"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.3324/haematol.2017.176859"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5830392"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5830392?pdf=render"}]}, "commentCorrectionList": {"commentCorrection": {"id": "29491127", "source": "MED", "reference": "Haematologica. 2018 Mar;103(3):377-379", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "8", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-03-06", "dateOfCreation": "2018-01-13", "firstIndexDate": "2018-01-12", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2021-04-26", "electronicPublicationDate": "2018-01-11", "firstPublicationDate": "2018-01-11"}, "htmllinks": "https://europepmc.org/articles/PMC5830392", "abstract": "Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft-<i>versus</i>-host disease incidence, with promising overall and progression-free survival. We performed an open-label three-arm 1:1:1 phase II randomized controlled trial comparing grade II-IV acute graft-<i>versus</i>-host disease between conventional tacrolimus/methotrexate (A) <i>versus</i> bortezomib/tacrolimus/methotrexate (B), and <i>versus</i> bortezomib/sirolimus/tacrolimus (C), in reduced intensity conditioning allogeneic transplantation recipients lacking HLA-matched related donors. The primary endpoint was grade II-IV acute graft-<i>versus</i>-host disease incidence rate by day +180. One hundred and thirty-eight patients (A 46, B 45, C 47) with a median age of 64 years (range: 24-75), varying malignant diagnoses and disease risk (low 14, intermediate 96, high/very high 28) received 7-8/8 HLA-mismatched (40) or matched unrelated donor (98) grafts. Median follow up in survivors was 30 months (range: 14-46). Despite early immune reconstitution differences, day +180 grade II-IV acute graft-<i>versus</i>-host disease rates were similar (A 32.6%, B 31.1%, C 21%; <i>P</i>=0.53 for A <i>vs</i> B, <i>P</i>=0.16 for A <i>vs</i> C). The 2-year non-relapse mortality incidence was similar (A 14%, B 16%, C 6.4%; <i>P</i>=0.62), as were relapse (A 32%, B 32%, C 38%; <i>P</i>=0.74), chronic graft-<i>versus</i>-host disease (A 59%, B 60% C 55%; <i>P</i>=0.66), progression-free survival (A 54%, B 52%, C 55%; <i>P</i>=0.95), and overall survival (A 61%, B 62%, C 62%; <i>P</i>=0.98). Overall, the bortezomib-based regimens evaluated did not improve outcomes compared with tacrolimus/methotrexate therapy. <i>clinicaltrials.gov Identifier: 01754389</i>.", "pdflinks": "https://europepmc.org/articles/PMC5830392?pdf=render", "journaltitle": "Haematologica", "authorinfo": ["Koreth J", "Kim HT", "Lange PB", "Poryanda SJ", "Reynolds CG", "Rai SC", "Armand P", "Cutler CS", "Ho VT", "Glotzbecker B", "Yusuf R", "Nikiforow S", "Chen YB", "Dey B", "McMasters M", "Ritz J", "Blazar BR", "Soiffer RJ", "Antin JH", "Alyea EP 3rd"], "title": "Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results."}